表紙
市場調査レポート

鬱血性心不全(心不全):パイプライン製品の分析

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245973
出版日 ページ情報 英文 397 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
鬱血性心不全(心不全):パイプライン製品の分析 Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016
出版日: 2016年03月22日 ページ情報: 英文 397 Pages
概要

鬱血性心不全は心不全は鬱血性心不全(CHF)としても知られています。CHFは、心臓がもはや酸素を豊富に含む血液を十分に送り出すことが出来ない状態です。症状には、咳、疲労感、虚弱、脱力感、食欲不振、肝臓または腹部の腫れ(肥大)、足・足首の腫れ、および体重増加などがあります。発病の要因には、高血圧、糖尿病、睡眠時無呼吸、アルコールの使用および不整脈が含まれます。治療には、外科手術、血管拡張剤、ベータブロッカー、および利尿薬などが用いられます。

当レポートでは、世界における鬱血性心不全治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 調査範囲

鬱血性心不全(心不全)の概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Amgen Inc.
  • AnGes MG, Inc.
  • Angion Biomedica Corp.
  • ARCA biopharma, Inc.
  • Ascelegen Therapeutics, Inc.
  • Asklepios BioPharmaceutical, Inc.
  • Asterias Biotherapeutics, Inc.
  • Athersys, Inc.
  • Bayer AG
  • BEAT BioTherapeutics Corp.
  • BioCardia, Inc.
  • Bristol-Myers Squibb Company
  • Capricor Therapeutics, Inc.
  • Celyad SA
  • FibroGen, Inc.
  • GlaxoSmithKline Plc
  • Glucox Biotech AB
  • Heart Metabolics Limited
  • Hemostemix Ltd
  • Innopharmax Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Juventas Therapeutics, Inc.
  • La Jolla Pharmaceutical Company
  • Laboratoires Pierre Fabre SA
  • Lee's Pharmaceutical Holdings Limited
  • Les Laboratoires Servier SAS
  • Lonestar Heart, Inc.
  • Mast Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • MI.TO. Technology S.r.L.
  • miRagen Therapeutics, Inc.
  • Novartis AG
  • Nuo Therapeutics, Inc.
  • 小野薬品工業
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • PharmaIN Corporation
  • PhaseBio Pharmaceuticals, Inc.
  • Pluristem Therapeutics Inc.
  • Quantum Genomics SA
  • Recardio GmbH
  • RedHill Biopharma Ltd.
  • Sanofi
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Target Heart Biotec Srl
  • Theravance Biopharma, Inc.
  • TiGenix NV
  • Torrent Pharmaceuticals Limited
  • Trevena, Inc.
  • U.S. Stem Cell, Inc.
  • UniQure N.V.
  • Vichem Chemie Research Ltd.
  • Vicore Pharma AB
  • Zensun (Shanghai) Sci & Tech Co., Ltd.

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (sacubitril + valsartan)
  • AAVS-100A1
  • ACP-01
  • AdipoCell
  • AdipoCell + MyoCell
  • aladorian sodium
  • ALD-201
  • AMG-986
  • ANG-4011
  • AntimiR-199a
  • ARX-720
  • BAY-1067197
  • BBR-12
  • beperminogene perplasmid
  • BNP-CHF
  • bucindolol hydrochloride
  • C-21
  • C3BSCQR-1
  • CAP-1002
  • carvedilol CR
  • carvedilol phosphate CR
  • cenderitide
  • CLR-325
  • CM-1
  • CTX-101
  • CXL-1036
  • CXL-1427
  • Drug for Heart Failure
  • Drug to Inhibit Calpain for Heart Failure
  • Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure
  • Drugs to Inhibit miR-425 for Hypertension and Heart Failure
  • ECR-A1
  • elamipretide
  • enalapril maleate
  • F-373280
  • FG-6874
  • FG-8205
  • finerenone
  • furosemide
  • GDF-11
  • Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure
  • Gene Therapy to Activate UCn 2 for Congestive Heart Failure
  • Gene Therapy to Inhibit GRK2 for Heart Failure
  • Gene Therapy to Inhibit Mef2 for Heart Failure
  • Gene Therapy to Target mAKAPbeta for Heart Failure
  • GSK-2798745
  • istaroxime
  • ITD-1
  • ivabradine hydrochloride
  • ivabradine hydrochloride SR
  • JVS-100
  • KBP-5074
  • MGN-9103
  • milrinone ER
  • MP-3167
  • MPC-150IM
  • MyoCell
  • MyoCell SDF-1
  • Neucardin
  • NM-922
  • Oligonucleotides for Heart Failure
  • omecamtiv mecarbil MR
  • ONO-4232
  • PB-1046
  • Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure
  • perhexiline maleate
  • PF-05285401
  • PHIN-1138
  • PL-3994
  • PLX-PAD
  • poloxamer
  • pyroglutaminated serpinin
  • QGC-101
  • REC-02
  • Recombinant Protein for Congestive Heart Failure
  • rivaroxaban
  • RT-100
  • RT-110
  • RT-210
  • S-38844
  • SAR-296968
  • serelaxin
  • serpinin
  • SG-1002
  • sildenafil citrate
  • Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders
  • Small Molecule to Inhibit NOX-4 for Heart Failure
  • Small Molecule to Inhibit ROMK for Hypertension and Heart Failure
  • Small Molecules for Chronic Heart Failure
  • Small Molecules for Diabetes and Congestive Heart Failure
  • Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis
  • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure
  • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases
  • Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain
  • Small Molecules to Inhibit PDE4 for Heart Failure
  • Small Molecules to Inhibit PDE5 for Cardiovascular Disease
  • Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Heart Failure and Metabolic Syndrome
  • Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders
  • sodium nitrite
  • SP-20202
  • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology
  • Stem Cell Therapy for Heart failure
  • Stem Cell Therapy for Heart Failure
  • Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy
  • Stem Cell Therapy for Myocardial Infarction and Heart Failure
  • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases
  • TD-0714
  • TR-4
  • TRC-4186
  • TRV-027
  • TRV-120023
  • ularitide
  • vepoloxamer
  • vericiguat
  • XC-002
  • Xcel-hCardP
  • XEN-105

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7552IDB

Summary

Global Markets Direct's, 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2016', provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
  • The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects
  • The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Congestive Heart Failure (Heart Failure) Overview
  • Therapeutics Development
    • Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview
    • Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis
  • Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies
  • Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes
  • Congestive Heart Failure (Heart Failure) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Congestive Heart Failure (Heart Failure) - Products under Development by Companies
  • Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes
  • Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • AnGes MG, Inc.
    • Angion Biomedica Corp.
    • ARCA biopharma, Inc.
    • Ascelegen Therapeutics, Inc.
    • Asklepios BioPharmaceutical, Inc.
    • Asterias Biotherapeutics, Inc.
    • Athersys, Inc.
    • Bayer AG
    • BEAT BioTherapeutics Corp.
    • BioCardia, Inc.
    • Bristol-Myers Squibb Company
    • Capricor Therapeutics, Inc.
    • Celyad SA
    • FibroGen, Inc.
    • GlaxoSmithKline Plc
    • Glucox Biotech AB
    • Heart Metabolics Limited
    • Hemostemix Ltd
    • Innopharmax Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Juventas Therapeutics, Inc.
    • La Jolla Pharmaceutical Company
    • Laboratoires Pierre Fabre SA
    • Lee's Pharmaceutical Holdings Limited
    • Les Laboratoires Servier SAS
    • Lonestar Heart, Inc.
    • Mast Therapeutics, Inc.
    • Merck & Co., Inc.
    • Mesoblast Limited
    • MI.TO. Technology S.r.L.
    • miRagen Therapeutics, Inc.
    • Novartis AG
    • Nuo Therapeutics, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Palatin Technologies, Inc.
    • Pfizer Inc.
    • PharmaIN Corporation
    • PhaseBio Pharmaceuticals, Inc.
    • Pluristem Therapeutics Inc.
    • Quantum Genomics SA
    • Recardio GmbH
    • RedHill Biopharma Ltd.
    • Sanofi
    • Stealth BioTherapeutics Inc.
    • Stemedica Cell Technologies, Inc.
    • Target Heart Biotec Srl
    • Theravance Biopharma, Inc.
    • TiGenix NV
    • Torrent Pharmaceuticals Limited
    • Trevena, Inc.
    • U.S. Stem Cell, Inc.
    • UniQure N.V.
    • Vichem Chemie Research Ltd.
    • Vicore Pharma AB
    • Zensun (Shanghai) Sci & Tech Co., Ltd.
  • Congestive Heart Failure (Heart Failure) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (sacubitril + valsartan) - Drug Profile
    • AAVS-100A1 - Drug Profile
    • ACP-01 - Drug Profile
    • AdipoCell - Drug Profile
    • AdipoCell + MyoCell - Drug Profile
    • aladorian sodium - Drug Profile
    • ALD-201 - Drug Profile
    • AMG-986 - Drug Profile
    • ANG-4011 - Drug Profile
    • AntimiR-199a - Drug Profile
    • ARX-720 - Drug Profile
    • BAY-1067197 - Drug Profile
    • BBR-12 - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • BNP-CHF - Drug Profile
    • bucindolol hydrochloride - Drug Profile
    • C-21 - Drug Profile
    • C3BSCQR-1 - Drug Profile
    • CAP-1002 - Drug Profile
    • carvedilol CR - Drug Profile
    • carvedilol phosphate CR - Drug Profile
    • cenderitide - Drug Profile
    • CLR-325 - Drug Profile
    • CM-1 - Drug Profile
    • CTX-101 - Drug Profile
    • CXL-1036 - Drug Profile
    • CXL-1427 - Drug Profile
    • Drug for Heart Failure - Drug Profile
    • Drug to Inhibit Calpain for Heart Failure - Drug Profile
    • Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure - Drug Profile
    • Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile
    • ECR-A1 - Drug Profile
    • elamipretide - Drug Profile
    • enalapril maleate - Drug Profile
    • F-373280 - Drug Profile
    • FG-6874 - Drug Profile
    • FG-8205 - Drug Profile
    • finerenone - Drug Profile
    • furosemide - Drug Profile
    • GDF-11 - Drug Profile
    • Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile
    • Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile
    • Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile
    • Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile
    • Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile
    • GSK-2798745 - Drug Profile
    • istaroxime - Drug Profile
    • ITD-1 - Drug Profile
    • ivabradine hydrochloride - Drug Profile
    • ivabradine hydrochloride SR - Drug Profile
    • JVS-100 - Drug Profile
    • KBP-5074 - Drug Profile
    • MGN-9103 - Drug Profile
    • milrinone ER - Drug Profile
    • MP-3167 - Drug Profile
    • MPC-150IM - Drug Profile
    • MyoCell - Drug Profile
    • MyoCell SDF-1 - Drug Profile
    • Neucardin - Drug Profile
    • NM-922 - Drug Profile
    • Oligonucleotides for Heart Failure - Drug Profile
    • omecamtiv mecarbil MR - Drug Profile
    • ONO-4232 - Drug Profile
    • PB-1046 - Drug Profile
    • Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile
    • perhexiline maleate - Drug Profile
    • PF-05285401 - Drug Profile
    • PHIN-1138 - Drug Profile
    • PL-3994 - Drug Profile
    • PLX-PAD - Drug Profile
    • poloxamer - Drug Profile
    • pyroglutaminated serpinin - Drug Profile
    • QGC-101 - Drug Profile
    • REC-02 - Drug Profile
    • Recombinant Protein for Congestive Heart Failure - Drug Profile
    • rivaroxaban - Drug Profile
    • RT-100 - Drug Profile
    • RT-110 - Drug Profile
    • RT-210 - Drug Profile
    • S-38844 - Drug Profile
    • SAR-296968 - Drug Profile
    • serelaxin - Drug Profile
    • serpinin - Drug Profile
    • SG-1002 - Drug Profile
    • sildenafil citrate - Drug Profile
    • Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile
    • Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile
    • Small Molecule to Inhibit ROMK for Hypertension and Heart Failure - Drug Profile
    • Small Molecules for Chronic Heart Failure - Drug Profile
    • Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile
    • Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile
    • Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
    • Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
    • Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile
    • Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile
    • Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
    • Small Molecules to Inversely Agonize Beta3-Adrenoreceptor for Cachexia, Heart Failure and Metabolic Syndrome - Drug Profile
    • Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile
    • sodium nitrite - Drug Profile
    • SP-20202 - Drug Profile
    • Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile
    • Stem Cell Therapy for Heart failure - Drug Profile
    • Stem Cell Therapy for Heart Failure - Drug Profile
    • Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile
    • Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile
    • Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
    • TD-0714 - Drug Profile
    • TR-4 - Drug Profile
    • TRC-4186 - Drug Profile
    • TRV-027 - Drug Profile
    • TRV-120023 - Drug Profile
    • ularitide - Drug Profile
    • vepoloxamer - Drug Profile
    • vericiguat - Drug Profile
    • XC-002 - Drug Profile
    • Xcel-hCardP - Drug Profile
    • XEN-105 - Drug Profile
  • Congestive Heart Failure (Heart Failure) - Recent Pipeline Updates
  • Congestive Heart Failure (Heart Failure) - Dormant Projects
  • Congestive Heart Failure (Heart Failure) - Discontinued Products
  • Congestive Heart Failure (Heart Failure) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2016
  • Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Angion Biomedica Corp., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by MI.TO. Technology S.r.L., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by UniQure N.V., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd., H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2016
  • Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Congestive Heart Failure (Heart Failure) Therapeutics - Recent Pipeline Updates, H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..8), H1 2016
  • Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..9), H1 2016
  • Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2016
  • Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2016
  • Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top